Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Petersenn

Showing results (91-100 of 123) with videos related to

Pageof 13
Sort By:
Pituitary|September 18, 2015
SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot studyAndrea Giustina, John S Bevan, Marcello D Bronstein, et al.
World Journal of Surgery|March 18, 2008
Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasiaMartin K Walz, Roland Gwosdz, Stephanie L Levin, et al.
Acta Neuropathologica Communications|August 20, 2015
Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modificationsChristian P Miermeister, Stephan Petersenn, Michael Buchfelder, et al.
European Journal of Endocrinology|December 6, 2019
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's diseaseJohn Newell-Price, Rosario Pivonello, Antoine Tabarin, et al.
The Journal of Clinical Endocrinology and Metabolism|October 8, 2019
Clinical Situation, Therapy, and Follow-Up of Adult CraniopharyngiomaKlaus Christian Mende, Teresa Kellner, Stephan Petersenn, et al.
Journal of Clinical Pharmacology|May 8, 2014
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I studyStephan Petersenn, Jens Bollerslev, Ayman M Arafat, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|December 7, 2020
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and SwitzerlandSylvère Störmann, Jochen Schopohl, Catharina Bullmann, et al.
Acta Neuropathologica Communications|March 18, 2016
Erratum: Histological criteria for atypical pituitary adenomas--data from the German pituitary adenoma registry suggests modificationsChristian P Miermeister, Stephan Petersenn, Michael Buchfelder, et al.
Clinical Endocrinology|February 19, 2014
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III studyRosario Pivonello, Stephan Petersenn, John Newell-Price, et al.
Clinical Endocrinology|August 30, 2019
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension studyMaria Fleseriu, Stephan Petersenn, Beverly M K Biller, et al.
Pageof 13

Showing results (91-100 of 123) with videos related to

Sort By:
Pageof 13
Pituitary|September 18, 2015
SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice--development and results from a pilot studyAndrea Giustina, John S Bevan, Marcello D Bronstein, et al.
World Journal of Surgery|March 18, 2008
Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasiaMartin K Walz, Roland Gwosdz, Stephanie L Levin, et al.
Acta Neuropathologica Communications|August 20, 2015
Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modificationsChristian P Miermeister, Stephan Petersenn, Michael Buchfelder, et al.
European Journal of Endocrinology|December 6, 2019
Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's diseaseJohn Newell-Price, Rosario Pivonello, Antoine Tabarin, et al.
The Journal of Clinical Endocrinology and Metabolism|October 8, 2019
Clinical Situation, Therapy, and Follow-Up of Adult CraniopharyngiomaKlaus Christian Mende, Teresa Kellner, Stephan Petersenn, et al.
Journal of Clinical Pharmacology|May 8, 2014
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I studyStephan Petersenn, Jens Bollerslev, Ayman M Arafat, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|December 7, 2020
Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and SwitzerlandSylvère Störmann, Jochen Schopohl, Catharina Bullmann, et al.
Acta Neuropathologica Communications|March 18, 2016
Erratum: Histological criteria for atypical pituitary adenomas--data from the German pituitary adenoma registry suggests modificationsChristian P Miermeister, Stephan Petersenn, Michael Buchfelder, et al.
Clinical Endocrinology|February 19, 2014
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III studyRosario Pivonello, Stephan Petersenn, John Newell-Price, et al.
Clinical Endocrinology|August 30, 2019
Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension studyMaria Fleseriu, Stephan Petersenn, Beverly M K Biller, et al.
Pageof 13